Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Azacitidine
Drug ID BADD_D00194
Description A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status approved; investigational
ATC Code L01BC07
DrugBank ID DB00928
KEGG ID D03021
MeSH ID D001374
PubChem ID 9444
TTD Drug ID D09FAZ
NDC Product Code 0781-9253; 14096-121; 81955-0012; 16729-306; 55150-393; 63323-771; 68001-527; 69097-368; 69097-805; 71288-153; 72485-201; 65129-1222; 68554-0104; 72606-558; 53183-4011; 43598-678; 59572-102; 51916-350; 83137-0006; 16714-927; 43817-906; 59572-730; 68001-504; 71288-115; 63660-0010; 0781-3253; 42385-312; 66529-0013; 54893-0029; 82920-015; 68001-313; 42385-719; 43598-305; 16714-578; 51991-797; 64679-096; 70121-1237; 63592-1800; 0143-9606; 43598-143; 43598-465; 59572-740
UNII M801H13NRU
Synonyms Azacitidine | 5-Azacytidine | 5 Azacytidine | Azacytidine | Vidaza | NSC-102816 | NSC 102816 | NSC102816
Chemical Information
Molecular Formula C8H12N4O5
CAS Registry Number 320-67-2
SMILES C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Leukaemia16.01.03.001; 01.10.03.0010.001455%
Leukocytosis01.02.01.0020.001175%
Leukoencephalopathy17.13.02.0030.000168%
Leukopenia01.02.02.0010.001981%Not Available
Liver disorder09.01.08.0010.001847%Not Available
Loss of consciousness17.02.04.004--Not Available
Lung consolidation22.01.02.0100.000168%Not Available
Lung disorder22.02.07.0010.000895%Not Available
Lung infiltration22.01.02.0040.000504%Not Available
Lymphadenopathy01.09.01.002--Not Available
Lymphoma16.20.01.001; 01.12.01.0010.000224%Not Available
Malaise08.01.01.003--
Marrow hyperplasia16.21.01.001; 01.13.01.0010.000112%Not Available
Mass08.03.05.0030.000112%Not Available
Melaena24.07.02.013; 07.12.02.0040.000560%Not Available
Monocytosis01.02.01.0040.000392%Not Available
Mouth haemorrhage24.07.02.014; 07.05.02.0010.000280%
Mucosal inflammation08.01.06.0020.000616%Not Available
Mucosal ulceration08.01.06.0030.000112%Not Available
Muscle haemorrhage12.01.07.016; 24.07.01.037; 15.05.03.0170.000112%Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myelodysplastic syndrome16.01.04.001; 01.10.04.0010.014539%
Myelofibrosis16.21.03.001; 01.13.03.0050.001007%Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia24.04.04.010; 02.02.02.0080.000616%Not Available
Myositis15.05.01.0010.000280%
Nasal congestion22.04.04.001--
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 19 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene